245 related articles for article (PubMed ID: 34338115)
1. Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe.
Agboton C; Salameh J
Expert Opin Biol Ther; 2022 Feb; 22(2):157-167. PubMed ID: 34338115
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
[TBL] [Abstract][Full Text] [Related]
4. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
Uhlig T; Goll GL
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars for the treatment of psoriatic arthritis.
Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
[No Abstract] [Full Text] [Related]
8. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
[No Abstract] [Full Text] [Related]
10. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in Dermatology - theory becomes reality.
Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
[TBL] [Abstract][Full Text] [Related]
12. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
[TBL] [Abstract][Full Text] [Related]
13. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico.
Mayoral-Zavala A; Esquivel-Aguilar A; Del Real-Calzada CM; Gutiérrez-Grobe Y; Ramos-García J; Rocha-Ramírez JL; Rojas-Illanes MF; Rubio-Martínez B; Sánchez-Chávez X; Yamamoto-Furusho JK;
Rev Gastroenterol Mex (Engl Ed); 2018; 83(4):414-423. PubMed ID: 29685744
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars for the treatment of psoriasis.
Puig L; López-Ferrer A
Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
[No Abstract] [Full Text] [Related]
16. Biosimilars: From Extrapolation into Off Label Use.
Zhao S; Nair JR; Moots RJ
Curr Pharm Des; 2017; 23(44):6746-6751. PubMed ID: 29189127
[TBL] [Abstract][Full Text] [Related]
17. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.
Moots R; Azevedo V; Coindreau JL; Dörner T; Mahgoub E; Mysler E; Scheinberg M; Marshall L
Curr Rheumatol Rep; 2017 Jun; 19(6):37. PubMed ID: 28623625
[TBL] [Abstract][Full Text] [Related]
18. Progress with infliximab biosimilars for inflammatory bowel disease.
Kurti Z; Gonczi L; Lakatos PL
Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
[TBL] [Abstract][Full Text] [Related]
19. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence studies with anti-TNF biosimilars.
Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F
Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813
[No Abstract] [Full Text] [Related]
[Next] [New Search]